Tec-Dara significantly improves PFS and OS compared to SoC in relapsed/refractory multiple myeloma
Tec-Dara significantly improves PFS and OS compared to SoC in relapsed/refractory multiple myeloma
Black patients show inferior survival despite similar cytogenetics and treatment response
Rocbrutinib shows strong responses in resistant CLL, including BTKi- and venetoclax-exposed patients
Choosing Wisely: Managing resectable colorectal liver metastases
Optimal management of gastric cancers
Do all hormone sensitive prostate cancers need triplet therapy?
Choosing Wisely: ctDNA/ Precision Oncology in colorectal cancers
Tarlatamab improves symptoms and QoL over chemo in previously treated SCLC
ESMO 2025: Latest developments in endometrial cancer
ESMO 2025: Precision medicine in bladder cancer
Tarlatamab plus chemo-IO shows promising efficacy in extensive stage SCLC
ESMO 2025: Highlights and analysis